Alzheimer's Association Workgroup Suggests Language for Clinicians to Talk to Their Patients About New Treatments
October 16, 2024
October 16, 2024
CHICAGO, Illinois, Oct. 16 (TNSres) -- The Alzheimer's Association issued the following news release:
The availability of FDA-approved therapies for early Alzheimer's disease challenges clinicians and healthcare providers with effectively communicating the risks, benefits, burdens, costs and available support associated with these treatments to patients, families and other health care providers. The task is essential but complex.
The Alzheimer's Association Clinical Mea . . .
The availability of FDA-approved therapies for early Alzheimer's disease challenges clinicians and healthcare providers with effectively communicating the risks, benefits, burdens, costs and available support associated with these treatments to patients, families and other health care providers. The task is essential but complex.
The Alzheimer's Association Clinical Mea . . .